<scp><i>PIK3CA</i></scp> mutational status in tissue and plasma as a prognostic biomarker in <scp>HR</scp>+/<scp>HER2−</scp> breast cancer
Our findings suggest the PIK3CA evaluation in tissue as the diagnostic method of choice, however, additional investigations are required to improve the role of liquid biopsy in the PIK3CA assessment. PIK3CAm show worse outcomes in advanced luminal BC, especially in exon 9 mutation carriers, despite visceral involvement, prior exposure to endocrine therapy or detection of PIK3CAm in plasma, with an unclear prognosis in early-stage disease. Nonetheless, this should be validated in a prospective cohort study.
Authors
- R. Lozano Mejorada (ORCID: https://orcid.org/0000-0001-9567-6385)
- Eduardo Terán (ORCID: https://orcid.org/0000-0001-5643-6506)
- Emilio Fonseca (ORCID: https://orcid.org/0000-0002-6810-133X)
- José Antonio Moreno-Muñoz (ORCID: https://orcid.org/0000-0003-2172-7412)
- Juan Carlos Montero (ORCID: https://orcid.org/0000-0003-4773-053X)
- María Dolores Ludeña de la Cruz (ORCID: https://orcid.org/0000-0003-3991-5956)
- B. Cigarral
- José María Sayagués (ORCID: https://orcid.org/0000-0003-0582-3500)
- D. Morchón Araujo (ORCID: https://orcid.org/0009-0005-2987-3950)
- César A. Rodríguez (ORCID: https://orcid.org/0000-0003-3484-4829)
- María Asunción Gómez
- Luis Figuero
- Mar Abad
- A. R. F. Rodrigues
Institutions
- Universidad de Salamanca (ES)
- Instituto de Investigación Biomédica de Salamanca (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/cam4.70101
- Citations
- 4
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Roche Diagnostics